TMCnet - World's Largest Communications and Technology Community



Bharat Book Bureau: Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
[December 20, 2013]

Bharat Book Bureau: Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

(M2 PressWIRE Via Acquire Media NewsEdge) Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

Sofosbuvir, previously known as GS-7977, is an HCV therapy being developed by Gilead, which obtained the rights to the drug through its acquisition of Pharmasset in November of 2011. As an NS5B nucleotide polymerase inhibitor, sofosbuvir exhorts its antiviral activity by mimicking the natural substrate of the viral RNA-dependent RNA polymerase.

Scope - Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Sofosbuvir and Sofosbuvir/Ledipasvir including product description, safety and efficacy profiles as well as a SWOT analysis.

For more information visit : OR Contact us at : Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Toll Free No for USA/Canada : 1-866-279-8368 For live chat : Email: Website: Follow us on twitter: Follow us on linkedin : Our Blog : ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at on the world wide web. Inquiries to


[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy